Stock Track | Dyne Therapeutics Soars 5.18% Intraday on Phase 3 Trial Launch and Positive Clinical Data
Stock Track
Mar 09
Dyne Therapeutics, Inc. (DYN) experienced a significant intraday surge, with its stock price soaring 5.18% during the trading session.
The sharp increase follows the company's announcement over the weekend that it has initiated a Phase 3 clinical study of its drug candidate, zeleciment basivarsen, for the treatment of myotonic dystrophy type 1, a rare genetic neuromuscular disease. Concurrently, Dyne Therapeutics reported positive data from an ongoing Phase 1/2 study of zeleciment rostudirsen for Duchenne muscular dystrophy, demonstrating improvements in patient lung function and heart performance compared to historical decline expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.